Part V — Peptides in Medicine

Chapters 25–31

Here is a question worth sitting with before this part starts.

Name three peptide drugs.

Most readers will manage insulin and semaglutide. Some will add growth hormone. Almost nobody names octreotide, which has been standard care for neuroendocrine tumors for decades. Or leuprolide, which has treated hundreds of thousands of cases of prostate cancer. Or teriparatide, which builds bone in severe osteoporosis by doing something genuinely counterintuitive. Or desmopressin, which children take for bedwetting and hemophilia patients take before surgery. Or vancomycin — a peptide antibiotic so routine that nobody thinks of it as a peptide at all.

More than eighty peptide drugs are approved and in daily clinical use. They are not fringe, not experimental, and not new. They are ordinary medicine, hiding in plain sight under names that do not sound like the ones on the forums.

That is Part V's first argument, and it reframes everything before and after it.

Why this changes the picture

If your entire exposure to peptides is Ozempic plus a biohacking podcast, the field looks like it has two states: a handful of blockbusters, and a large gray zone of speculation.

Part V shows you the enormous, unglamorous middle — a mature therapeutic class with decades of clinical experience, spread across oncology, endocrinology, cardiology, critical care, infectious disease, and dermatology. Once you have seen it, two things become obvious.

First: peptides work as drugs. The category is not speculative. The question is never "can a peptide be a real medicine" — it is "does this peptide, for this claim, have the evidence."

Second: the successful ones have a shape. Look across Part V's ✅ ratings and a pattern appears. The peptide drugs that worked overwhelmingly do one of three things: they replace a hormone the patient is missing, they block a receptor in a system that is overactive, or they deliver something to a specific address. What almost never works is the vaguest and most popular claim in the consumer space — a peptide that broadly "supports," "optimizes," or "modulates" a healthy system. Chapter 37 makes that pattern explicit; Part V is where you accumulate the evidence for it.

The seven chapters

Chapter 25 — Antimicrobial Peptides takes on the crisis that could reorganize medicine. Antibiotic-resistant infections are attributable to roughly 1.27 million deaths a year, and antimicrobial peptides — an ancient defense system every living thing has — attack bacteria by physically disrupting membranes rather than by inhibiting a specific enzyme, which makes resistance harder to evolve. The obstacles are real: our cells have membranes too, and manufacturing is expensive. A careful 🔬.

Chapter 26 — Peptide Vaccines explains that an immune system is trained by peptides. Vaccines present epitopes — short peptide fragments — and the immune system learns them. Personalized cancer vaccines take this to its logical conclusion: sequence a patient's tumor, identify the mutations unique to it, and build a vaccine against that individual's cancer. Extraordinary idea, real trials running, genuinely too early to rate.

Chapter 27 — Peptides in Oncology covers the class most readers do not know exists: GnRH agonists and antagonists that shut down hormone axes, somatostatin analogs that control neuroendocrine tumors, and radioligand therapy — where a peptide's only job is to be an address, carrying a radioactive payload to cells that display a particular receptor. Decades of use, strong evidence, and almost no public awareness.

Chapter 28 — Natriuretic Peptides is a two-role story. The heart releases peptides when it is stretched, which makes them the most important blood test in heart failure diagnosis — and makes them tempting as treatments. The biomarker use earned a ✅. The direct-infusion drug did not survive its outcome trial. But a drug that prevents their breakdown transformed heart failure care. Same system, three completely different verdicts.

Chapter 29 — The Peptide Drugs Already in Your Pharmacy is the pharmacopeia tour: teriparatide, desmopressin, calcitonin, glucagon rescue, terlipressin, icatibant, linaclotide, and the peptides nobody labels as such. This chapter is the most quietly persuasive in the book.

Chapter 30 — Peptides in Dermatology and Cosmetics answers the \$90 bottle question. There is a real mechanism underneath cosmetic peptides — some of these sequences genuinely do signal for collagen in a dish. The problem is between the dish and your dermis, and it is called the stratum corneum. The chapter separates injected peptides (which work spectacularly) from topical ones (which mostly face a physics problem), and reads a cosmetic study the way Chapter 5 taught you to.

Chapter 31 — Peptides in Veterinary Medicine closes the loop on Part III. Several compounds popular with human users were developed for, or are primarily used in, animals. That is a real fact with a real history — and it is a question, not a credential. Species differ in metabolism, dose scaling, and physiology, and "it's been used for years" always requires the follow-up: in whom?

What Part V asks you to notice

Every chapter here contains at least one reversal — a peptide that looked promising and failed, or one that looked marginal and became standard care, or one whose approved use and popular use are completely different things.

Those reversals are the curriculum. A field where everything worked as predicted would not need an evidence-evaluation method. This one does.

📋 Your Evidence Dossier — Part V

Chapter 27 teaches you to read a drug label as evidence — indication, population, line of therapy, and what the approval actually certifies. It is the single most underrated research skill available to a non-specialist, and the information is free.

Chapter 28 adds a distinction that will save you from a common error: the same peptide in two roles gets two ratings. A molecule can be an excellent biomarker and a failed drug. Those are different claims, tested by different studies, and conflating them is how "the science says" turns into something the science did not say.

Chapters in This Part